CLYM

Climb Bio, Inc. NASDAQ Listed Aug 10, 2021

Healthcare ·Biotechnology ·US · eliemtx.com

$11.91

After hrs $11.85 +4.22%

Mkt Cap $812.1M

52w Low $1.13 95.0% of range 52w High $12.48

50d MA $7.91 200d MA $4.12

P/E (TTM) -10.1x

EV/EBITDA -3.5x

P/B 3.8x

Debt/Equity 0.0x

ROE -37.3%

P/FCF -5.0x

RSI (14) —

ATR (14) —

Beta -0.20

50d MA $7.91

200d MA $4.12

Avg Volume 570.8K

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

SIC Code

2834

CIK (SEC)

1768446

Phone

866 857 2596

PMB #117, 2801 Centerville Road · Wellesley Hills, DE 19808-1609 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.20	-0.26	-30.0%	7.39	-0.4%	-2.8%	-1.9%	-0.8%	-0.8%	-1.8%	—
Nov 6, 2025	AMC	-0.16	-0.19	-18.8%	1.95	-3.1%	-6.2%	-7.7%	-2.6%	-1.5%	-4.1%	—
Aug 12, 2025	AMC	-0.19	-0.13	+31.6%	1.61	+2.5%	+1.2%	+6.8%	+18.0%	+31.1%	+25.5%	—
May 14, 2025	AMC	-0.15	-0.31	-106.7%	1.17	+0.0%	+2.6%	+10.3%	+8.5%	+6.0%	+3.4%	—
Mar 25, 2025	AMC	-0.15	-0.13	+13.3%	1.30	+3.1%	+0.0%	-2.3%	-1.5%	-6.2%	-7.7%	—
Nov 12, 2024	AMC	—	-0.13	—	3.80	+6.3%	-7.1%	-15.8%	-20.8%	-19.5%	-14.5%	—
Aug 14, 2024	AMC	—	-1.81	—	—	—	—	—	—	—	—	—
May 15, 2024	AMC	—	-0.06	—	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	-0.13	-0.13	-2.5%	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	-0.14	-0.15	-4.7%	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	-0.16	-0.19	-21.6%	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	-0.25	-0.84	-236.0%	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 5	Chardan Capital Markets	Initiates	Buy	$22	$9.69	$9.93	+2.5%	+18.2%	+26.1%	+22.9%	—	—
Apr 21	Oppenheimer	Maintains	Outperform → Outperform	—	$8.97	$9.24	+3.0%	+4.5%	+3.7%	+0.6%	+1.9%	+5.9%
Apr 8	BTIG	Maintains	Buy → Buy	—	$6.87	$7.10	+3.3%	+3.3%	+17.2%	+22.4%	+25.6%	+28.8%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.25	$7.48	+3.2%	+1.1%	+1.1%	+0.1%	-3.0%	-1.7%
Mar 6	Baird	Maintains	Outperform → Outperform	—	$7.39	$7.36	-0.4%	-2.8%	-1.9%	-0.8%	-0.8%	-1.8%
Mar 6	Wedbush	Maintains	Outperform → Outperform	—	$7.39	$7.36	-0.4%	-2.8%	-1.9%	-0.8%	-0.8%	-1.8%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.25	$4.33	+1.9%	+3.1%	+0.7%	+15.3%	+8.2%	+14.1%
Oct 16	BTIG	Maintains	Buy → Buy	—	$1.94	$2.06	+6.2%	+0.5%	-0.5%	+19.6%	+16.5%	+6.2%
Sep 30	BTIG	Maintains	Buy → Buy	—	$1.99	$1.99	+0.0%	+1.0%	-1.0%	+2.5%	-0.5%	-9.0%
Sep 22	BTIG	Maintains	Buy → Buy	—	$2.31	$2.42	+4.8%	+0.4%	-2.6%	-5.2%	-9.1%	-7.8%

Data updated apr 25, 2026 1:52am · Source: massive.com